EEEllen F. Eaton

Ellen F. Eaton

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ellen F. Eaton has a total of 131 co-authors. Here are the top co-authors by number of shared publications:

  • Michael J. Mugavero

    Division of Infectious Diseases, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, USA

    6 shared publications
  • Michael S. Saag

    University of Alabama at Birmingham, Division of Infectious Diseases, 1900 University Boulevard, Tinsley Harrison Tower, Birmingham, AL 35294, USA

    5 shared publications
  • Greer A. Burkholder

    University of Alabama at Birmingham, Birmingham, AL, USA

    4 shared publications
  • Ashutosh Tamhane

    University of Alabama at Birmingham, Division of Infectious Diseases, 1900 University Boulevard, Tinsley Harrison Tower, Birmingham, AL 35294, USA

    3 shared publications
  • Ashutosh Tamhane

    Division of Nephrology, Department of Medicine, University of Alabama at Birmingham , Birmingham, Alabama

    3 shared publications
  • Kelly W. Gagnon

    Affiliation Division of Infectious Diseases, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States of America

    3 shared publications

Latest Publications

  • Open Access

    Infections and the Opioid Epidemic: Changing Epidemiology and Treatment Options

    by Laura C. Fanucchi, Ellen Eaton, Nicholas Van Sickels, Michelle R. Lofwall

    The opioid epidemic has led to an infectious diseases syndemic, with injection drug use responsible for driving rising rates of HIV, viral hepatitis, and serious bacterial and fungal infections. Opioid use continues to cause devastating mortality, with over 80,000 opioid-involved overdose deaths in the USA in 2022. Despite the proven effectiveness of opioid agonist therapy, specifically methadone and buprenorphine, treatment coverage remains inadequate, with profound gaps in opioid use disorder (OUD) continuum of care. Injection-related infections, particularly skin and soft tissue infections, bacteremia, osteomyelitis, and infective endocarditis, have increased substantially since the early 2000s and carry a high risk of morbidity and mortality. Risk is further compounded by criminalization, stigma, incarceration, and comorbid psychiatric conditions. Emerging concerns such as xylazine-associated necrotic wounds illustrate the dynamic intersection of substance use and infectious disease. While direct-acting antivirals have made hepatitis C curable, barriers to treatment persist, and uptake of HIV prevention strategies, including pre-exposure prophylaxis, remains low among people who inject drugs. Integration of addiction treatment into infectious disease and hospital care improves outcomes, yet systemic and policy barriers limit access. Innovative models such as syringe service programs, mobile units, and inpatient addiction consult services demonstrate the feasibility of integrated, patient-centered care. Evidence gaps remain regarding optimal antibiotic strategies for serious infections in people with OUD, and research and policy must address exclusionary practices, stigma, and fragmented systems of care. A synergistic approach integrating OUD treatment, infectious disease management, risk reduction, and trauma-informed care is essential to reduce preventable deaths and improve long-term health outcomes.

  • Open Access

    Optimizing Treatment of Infective Endocarditis in Patients Who Inject Drugs

    by Jarett Worden, Tyler Baumeister, Ellen Eaton

    The treatment of infective endocarditis (IE) in patients who inject drugs (PWID) is complex and challenging. These patients face stigma in the healthcare system, as well as higher mortality, longer length of hospital stay, higher rates of recurrent infections, and lower likelihood of antibiotic completion. Standard treatment for IE involves several weeks of antibiotics. For PWID, these prolonged courses often mean intravenous antibiotics administered in the inpatient setting for at least 4 to 6 weeks, which increases both healthcare costs and the risk of patient-directed discharge against medical advice. Effective treatment of IE in PWID involves a combination of addiction management and appropriate antibiotic therapy. To promote rational use of healthcare resources and optimize antibiotic stewardship, novel approaches to antibiotic therapy must be utilized. This review discusses evidence supporting treatment strategies outside of the inpatient hospital setting, including outpatient parenteral antibiotic therapy (OPAT), long-acting lipoglycopeptides, and oral antibiotic therapy for the treatment of endocarditis. Optimal treatment of IE in PWID involves support from a multidisciplinary healthcare team, management of substance use disorder, and effective antibiotic therapy.

  • Open Access

    Barriers and facilitators to implementing electronic patient reported outcome screening for mental illness and substance use disorders at HIV clinics in Alabama: a qualitative study

    by Ellen Eaton, C. Greer McCollum, Kelly W. Gagnon, Anna-Julia Enid Kutsch, Kaylee Burgan

    People living with HIV face disproportionately high rates of mental health issues (MH) and substance use disorders (SUD), which can contribute to reduced antiretroviral treatment (ART) adherence. When left untreated, these psychosocial comorbidities pose an additional threat to the goals of the Ending HIV Epidemic Initiative, which aims to optimize HIV outcomes in states like Alabama, where the rural burden of HIV is among the highest in the nation. Fortunately, electronic patient reported outcome measures (ePROs) are effective in screening for MH and SUD in a wide variety of care settings, facilitating early referrals to evidence-based interventions. In this study, we use the Consolidated Framework for Implementation Research (CFIR) to identify barriers and facilitators to the implementation of depression, anxiety, and SUD ePROs in HIV clinics in Alabama, an Ending the HIV Epidemic Priority Jurisdiction. We interviewed 15 clinical and non-clinical staff at five Ryan White HIV/AIDS Program (RWHP) funded HIV clinics in Alabama. We queried their experiences with an ePRO intervention starting in 2022. We used a rapid analysis technique to explore themes related to the Characteristics of Individuals, Process, Characteristics of Innovation, and Inner Setting domains of CFIR. Two experienced qualitative researchers conducted the semi-structured interviews and iteratively analyzed the transcripts. We identified a variety of barriers and facilitators to implementation of MH and SUD ePROs in HIV clinics that fell under all four included domains. Participants reported significant staff turnover and/or limited staff capacity as primary barriers to consistent implementation. Sites also reported the lack of ongoing training and onboarding at the site level as a barrier that further impeded capacity and understanding. Positively, though, participants also reported that the intervention enhanced patient-provider communication and increased the rate of MH and SUD identification. Having a site champion as the primary point of contact, both internally and externally to the investigation team, was a key facilitator. The champions also increased team motivation and kept the intervention on track. Tablets were key to the intervention, enabling automatic results of ePROs. Despite numerous barriers, such as staff turnover, participants found the intervention to be easy to use, brief, and effective. This success was largely attributed to several facilitating factors, such as the use of tablets and the support of site champions.

  • A Study Protocol to Increase Engagement in Evidence-Based Hospital and Community-Based Care Using a Serious Injection-Related Infections Checklist and Intensive Peer for Hospitalized PWID (ShaPe)

    by Margaret Baldwin, Madison Jeziorski, Mariel Parman, Kelly W. Gagnon, Alana C. Nichols, Davis Bradford, Kaylee Crockett, Ellen F. Eaton

    With the ongoing drug crisis, serious injection-related infections (SIRIs), such as endocarditis, have increased significantly. Hospitalizations are a missed opportunity for persons who inject drugs (PWID) to engage in care. We developed a 5-item SIRI Checklist for providers as a standardized reminder to offer medication for opioid use disorder (MOUD), human immunodeficiency virus (HIV), and hepatitis C virus (HCV) screening, harm reduction, and referral to community-based care. We formalized an Intensive Peer Recovery Coach protocol to support PWID on discharge. We hypothesized that the SIRI Checklist and Intensive Peer Intervention would increase HIV and HCV screening, MOUD, and linkage to care: pre-exposure prophylaxis (PrEP) prescription, MOUD prescription, and related outpatient visit(s). This is a feasibility study and randomized control trial of a Checklist and Intensive Peer intervention for hospitalized PWID with SIRI. We will randomize 60 PWID into 4 groups (SIRI Checklist, SIRI Checklist + Intensive Peer, Intensive Peer, and Standard of Care). Results will be analyzed using a 2 Ă— 2 factorial design. Outcomes include the ability to recruit and retain hospitalized PWID and clinical data (HIV, HCV testing, MOUD, and PrEP prescriptions). By testing low-barrier interventions that are accessible and reproducible in a rural, poor state, we aim to identify models of care that promote linkage and engagement in community care.

  • Open Access

    Equal Access, Equal Outcomes: Telehealth Utilization Around the COVID-19 Pandemic among People Living with HIV and Opioid Use Disorder in the Deep South

    by William S Bradford, Julie England, Reed W R Bratches, Ellen F Eaton

    Telehealth has the potential to extend access to lifesaving treatment for opioid use disorder (OUD) among underserved people living with HIV (PWH). However, policymakers have scaled back pandemic-era telehealth provisions, citing concerns about safety and effectiveness. In this study of 42 PWH with OUD in one Deep South HIV clinic between 3/1/2020 and 4/30/2021, we used multivariable regression to assess the impact of telehealth utilization on patient-centered HIV and OUD outcomes. We found no significant difference in outcomes for those with high telehealth utilization versus others. In addition to being more accessible, telehealth does not appear to compromise health outcomes.


  • Open Access

    Injection Drug Use Alters Plasma Regulation of the B Cell Response

    by Sanghita Sarkar, Dave D. Hill, Alexander F. Rosenberg, Ellen F. Eaton, Olaf Kutsch, James J. Kobie

    The opioid epidemic continues to be a major public health issue that includes millions of people who inject drugs (PWID). PWID have increased incidence of serious infections, including HIV as well as metabolic and inflammatory sequelae. We sought to discern the extent of systemic alterations in humoral immunity associated with injection drug use, including alterations in the plasma proteome and its regulation of B cell responsiveness. Comprehensive plasma proteomics analysis of HIV negative/hepatitis C negative individuals with a history of recent injection heroin use was performed using mass spectrometry and ELISA. The effects of plasma from PWID and healthy controls on the in vitro proliferation and transcriptional profile of B cell responses to stimulation were determined by flow cytometry and RNA-Seq. The plasma proteome of PWID was distinct from healthy control individuals, with numerous immune-related analytes significantly altered in PWID, including complement (C3, C5, C9), immunoglobulin (IgD, IgM, kappa light chain), and other inflammatory mediators (CXCL4, LPS binding protein, C-reactive protein). The plasma of PWID suppressed the in vitro proliferation of B cells. Transcriptome analysis indicated that PWID plasma treatment increased B cell receptor and CD40 signaling and shifted B cell differentiation from plasma cell-like toward germinal center B cell-like transcriptional profiles. These results indicate that the systemic inflammatory milieu is substantially altered in PWID and may impact their B cell responses.

  • Open Access

    Community-Based Services for Hospitalized Patients With Serious Injection-Related Infections in Alabama: A Brief Report

    by Kelly W Gagnon, William Bradford, John Bassler, Ariann Nassel, Emma Sophia Kay, Madison Jeziorski, Myles Prados, Brandi McCleskey, James Kobie, Ellen Eaton

    Injection-related infections continue to rise, particularly in the South. People who inject drugs are increasingly utilizing hospital services for serious injection-related infections but may be discharged to areas without harm reduction services. We explored the availability and travel time to services for HIV and substance use in Alabama.


  • Open Access

    Brief Report: Substance Use Care Continuum in Women With and Without HIV in the Southern United States

    by Aditi Md Msc Ramakrishnan, Ayako W. Md Msc Fujita, C. Christina Mehta, Tracey E. Wilson, Steve Shoptaw, Adam Carrico, Adaora A. Adimora, Ellen F. Eaton, Deborah L. Jones, Aruna Chandran, et al.

    Background: Substance use (SU) contributes to poor outcomes among persons living with HIV. Women living with HIV (WWH) in the United States are disproportionately affected in the South, and examining SU patterns, treatment, and HIV outcomes in this population is integral to addressing HIV and SU disparities. Methods: WWH and comparable women without HIV (WWOH) who enrolled 2013–2015 in the Women's Interagency HIV Study Southern sites (Atlanta, Birmingham/Jackson, Chapel Hill, and Miami) and reported SU (self-reported nonmedical use of drugs) in the past year were included. SU and treatment were described annually from enrollment to the end of follow-up. HIV outcomes were compared by SU treatment engagement. Results: At enrollment, among 840 women (608 WWH, 232 WWOH), 18% (n = 155) reported SU in the past year (16% WWH, 24% WWOH); 25% (n = 38) of whom reported SU treatment. Over time, 30%, 21%, and 18% reported SU treatment at 1, 2, and 3 years, respectively, which did not significantly differ by HIV status. Retention in HIV care did not differ by SU treatment. Viral suppression was significantly higher in women who reported SU treatment only at enrollment (P = 0.03). Conclusions: We identified a substantial gap in SU treatment engagement, with only a quarter reporting treatment utilization, which persisted over time. SU treatment engagement was associated with viral suppression at enrollment but not at other time points or with retention in HIV care. These findings can identify gaps and guide future strategies for integrating HIV and SU care for WWH.


  • Open Access

    Delivery of the HIV Service and Telemedicine Through Effective Patient-Reported Outcomes (+STEP) Intervention to Increase Screening and Treatment of Mental Health and Substance Use Disorders for People Living With HIV in Alabama: Protocol for an Effectiveness-Implementation Study

    by Kelly W Gagnon, Stefan Baral, Dustin Long, Alfredo L Guzman, Bernadette Johnson, Greer Burkholder, James Willig, Michael Mugavero, Margaret Baldwin, Susanne Fogger, et al.

    Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: The syndemic of mental health (MH) and substance use disorders (SUDs) are common among persons living with HIV (PLWH) and jeopardize HIV treatment adherence, engagement in care, and viral load suppression. Electronic patient reported outcomes (ePROs), conducted via tablet or computer, and telemedicine are evidence- and technology-based interventions that have been used to successfully increase screening and treatment, respectively, a model that holds promise for PLWH. To date, there has been no guidance on how to implement ePROs and telemedicine into practice even though it is well-known that these evidence-based tools improve diagnosis and access to care. Objective: To address this, we are conducting a multicomponent intervention for PLWH, delivery of HIV services and Telemedicine through Effective ePROs (+STEP), to increase screening and treatment of MH and SUD in Ryan White HIV/AIDS Program (RWHAP)-funded clinics in Alabama. Methods: The Aims of this intervention are to: Aim 1) Conduct a needs assessment and implement +STEP to improve diagnosis and treatment of mental health (MH) and SUD at RWHAP clinics in Alabama; Aim 2) Describe implementation strategies that address barriers to uptake of +STEP in RWHAP clinics. We will conduct qualitative interviews in years 1 (early implementation), 2 (scale up), and 4 (maintenance) with patients and stakeholders (clinicians, staff) to evaluate barriers, facilitators, and implementation strategies. Results will enable us to modify strategies to enhance +STEP penetrance over time and inform the implementation blueprint, which we will develop for both RWHAP clinics in AL and future sites; Aim 3) Measure the impact of implementing +STEP on diagnoses, referrals, and healthcare utilization related to MH, SUD, and HIV by comparing clinical outcomes from patients receiving these interventions (ePROs, telemedicine) with historical controls. Results: The results of this study will provide a foundation for future research expanding access to ePROs for improved diagnosis linked to telemedicine access to accelerate patients along the continuum of care from MH and/or SUD diagnosis to treatment. Conclusions: Achieving the end of the HIV epidemic in the United States necessitates programs that accelerate movement across the MH and SUD care continuum from diagnosis to treatment for PLWH. Scaling these services represents a path towards improved treatment outcomes with both individual health and population level prevention benefits of sustained HIV viral suppression in the era of Undetectable = Untransmittable (U=U). Our study will address this evidence gap through the evaluation of implementation of +STEP to establish necessary systems and processes to screen, identify, and better treat substance use and mental health for people living with HIV.


  • Open Access

    Expanding access to substance use services and mental health care for people with HIV in Alabama, a technology readiness assessment using a mixed methods approach

    by Ellen F. Eaton, Kaylee Burgan, Greer McCollum, Sera Levy, James Willig, Michael J. Mugavero, Sushanth Reddy, Eric Wallace, Tom Creger, Stefan Baral, et al.

    Background: Alabama is one of seven priority states for the National Ending the HIV Epidemic Initiative due to a large rural burden of disease. Mental health (MH) and substance use disorders (SUD) represent obstacles to HIV care in rural areas lacking Medicaid expansion and infrastructure. Evidence-informed technologies, such as telehealth, may enhance SUD and MH services but remain understudied in rural regions. Methods: We conducted a readiness assessment using a mixed methods approach to explore opportunities for enhanced SUD and MH screening using electronic patient reported outcomes (ePROs) and telehealth at five Ryan White HIV/AIDS Program-funded clinics in AL. Clinic providers and staff from each site (N = 16) completed the Organizational Readiness to Implement Change (ORIC) assessment and interviews regarding existing services and readiness to change. People with HIV from each site (PLH, N = 18) completed surveys on the acceptability and accessibility of technology for healthcare. Results: Surveys and interviews revealed that all clinics screen for depression annually by use of the Patient Health Questionnaire-9 (PHQ9). SUD screening is less frequent and unstandardized. Telehealth is available at all sites, with three of the five sites beginning services due to the COVID-19 pandemic; however, telehealth for MH and SUD services is not standardized across sites. Results demonstrate an overall readiness to adopt standardized screenings and expand telehealth services beyond HIV services at clinics. There were several concerns including Wi-Fi access, staff capacity, and patients’ technological literacy. A sample of 18 people with HIV (PWH), ages 18 to 65 years, participated in surveys; all demonstrated adequate technology literacy. A majority had accessed telehealth and were not concerned about it being too complicated or limiting communication. There were some concerns around lack of in-person interaction and lack of a physical exam and high-quality care with telehealth. Conclusion: This study of PWH and the clinics that serve them reveals opportunities to expand SUD and MH services in rural regions using technology. Areas for improvement include implementing routine SUD screening, expanding telehealth while maintaining opportunities for in-person interaction, and using standardized ePROs that are completed by patients, in order to minimize stigma and bias.